MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-14-2026
Smith & Nephew plc Revenue 2011-2026 | SNN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Smith & Nephew plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.56 B | 5.14 B | 4.9 B | 4.76 B | 4.67 B | 4.63 B | 4.62 B | 4.35 B | 4.14 B | 4.27 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.14 B | 4.14 B | 4.6 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
764 M | $ 11.75 | -3.29 % | $ 1.76 B |  USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 8.98 | -1.32 % | $ 322 M | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.41 | 0.38 % | $ 121 M | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
349 M | $ 6.32 | -2.02 % | $ 168 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 100.97 | 1.78 % | $ 1.28 B | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 62.4 | -1.33 % | $ 3.4 B |  Britain |
 |
LENSAR
LNSR
|
53.5 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Medtronic PLC
MDT
|
33.5 B | $ 86.58 | -0.68 % | $ 111 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
64 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
InspireMD
NSPR
|
8.98 M | $ 1.79 | 3.47 % | $ 115 M | Israel |
 |
Orthofix Medical
OFIX
|
822 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
574 K | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
Profound Medical Corp.
PROF
|
7.2 M | $ 5.15 | -4.63 % | $ 180 M | Canada |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
1.4 B | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
40.9 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
Quanterix Corporation
QTRX
|
139 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
119 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |